Latest Insider Transactions at Ionis Pharmaceuticals Inc (IONS)
This section provides a real-time view of insider transactions for Ionis Pharmaceuticals Inc (IONS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of IONIS PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of IONIS PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 15
2022
|
Frederick T Muto Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,998
+6.42%
|
-
|
|
Jul 15
2022
|
Joseph Loscalzo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,998
+10.91%
|
-
|
|
Jul 15
2022
|
Joseph Klein Iii Director |
SELL
Open market or private sale
|
Direct |
1,333
-3.37%
|
$50,654
$38.26 P/Share
|
|
Jul 15
2022
|
Joseph Klein Iii Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,998
+17.55%
|
-
|
|
Jul 15
2022
|
Michael R Hayden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,110
+14.56%
|
-
|
|
Jul 15
2022
|
Joan E Herman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,110
+11.95%
|
-
|
|
Jul 15
2022
|
Allene M. Diaz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+50.0%
|
-
|
|
Jul 15
2022
|
Spencer R Berthelsen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,998
+3.04%
|
-
|
|
Jul 01
2022
|
Frederick T Muto Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+17.9%
|
$135,000
$12.94 P/Share
|
|
Jun 10
2022
|
Joan E Herman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,555
+15.38%
|
-
|
|
Jun 07
2022
|
Spencer R Berthelsen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+8.51%
|
$135,000
$12.94 P/Share
|
|
Apr 21
2022
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
378
-1.82%
|
$16,632
$44.15 P/Share
|
|
Apr 18
2022
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
SELL
Payment of exercise price or tax liability
|
Direct |
1,960
-13.95%
|
$80,360
$41.01 P/Share
|
|
Apr 18
2022
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
BUY
Exercise of conversion of derivative security
|
Direct |
5,667
+28.74%
|
-
|
|
Apr 12
2022
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
6,792
-16.43%
|
$271,680
$40.06 P/Share
|
|
Apr 01
2022
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
355
-0.4%
|
$13,135
$37.49 P/Share
|
|
Feb 28
2022
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
346
+0.62%
|
$9,688
$28.37 P/Share
|
|
Feb 28
2022
|
Richard S Geary EVP, Chief Development Officer |
BUY
Other acquisition or disposition
|
Direct |
621
+1.09%
|
$17,388
$28.37 P/Share
|
|
Feb 28
2022
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Other acquisition or disposition
|
Direct |
384
+0.65%
|
$10,752
$28.37 P/Share
|
|
Feb 28
2022
|
Brett P Monia Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
621
+0.69%
|
$17,388
$28.37 P/Share
|
|
Feb 28
2022
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Other acquisition or disposition
|
Direct |
735
+1.75%
|
$20,580
$28.37 P/Share
|
|
Feb 28
2022
|
Eric Swayze EVP Research |
BUY
Other acquisition or disposition
|
Direct |
621
+2.91%
|
$17,388
$28.37 P/Share
|
|
Jan 26
2022
|
Brett P Monia Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,032
-8.33%
|
$248,992
$31.44 P/Share
|
|
Jan 26
2022
|
Brett P Monia Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,198
+7.64%
|
-
|
|
Jan 18
2022
|
Eric Swayze EVP Research |
SELL
Payment of exercise price or tax liability
|
Direct |
4,994
-19.89%
|
$149,820
$30.12 P/Share
|
|
Jan 18
2022
|
Eric Swayze EVP Research |
BUY
Exercise of conversion of derivative security
|
Direct |
13,809
+35.49%
|
-
|
|
Jan 18
2022
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Payment of exercise price or tax liability
|
Direct |
3,815
-21.71%
|
$114,450
$30.12 P/Share
|
|
Jan 18
2022
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
BUY
Exercise of conversion of derivative security
|
Direct |
10,400
+37.18%
|
-
|
|
Jan 18
2022
|
Richard S Geary EVP, Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,605
-12.0%
|
$228,150
$30.12 P/Share
|
|
Jan 18
2022
|
Richard S Geary EVP, Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,391
+25.24%
|
-
|
|
Jan 18
2022
|
Brett P Monia Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
19,714
-19.73%
|
$591,420
$30.12 P/Share
|
|
Jan 18
2022
|
Brett P Monia Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
49,475
+33.11%
|
-
|
|
Jan 18
2022
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,828
-11.9%
|
$234,840
$30.12 P/Share
|
|
Jan 18
2022
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,050
+25.1%
|
-
|
|
Jan 18
2022
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
7,501
-15.6%
|
$225,030
$30.12 P/Share
|
|
Jan 18
2022
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
21,086
+30.48%
|
-
|
|
Jan 18
2022
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,726
-10.92%
|
$201,780
$30.12 P/Share
|
|
Jan 18
2022
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,842
+23.42%
|
-
|
|
Jan 18
2022
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
SELL
Payment of exercise price or tax liability
|
Direct |
2,305
-21.57%
|
$69,150
$30.12 P/Share
|
|
Jan 18
2022
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
BUY
Exercise of conversion of derivative security
|
Direct |
6,057
+36.17%
|
-
|
|
Jan 18
2022
|
B Lynne Parshall Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,652
-2.09%
|
$49,560
$30.12 P/Share
|
|
Jan 18
2022
|
B Lynne Parshall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,754
+6.78%
|
-
|
|
Oct 15
2021
|
Michael R Hayden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,777
+11.11%
|
-
|
|
Oct 15
2021
|
Peter N Reikes Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,777
+11.11%
|
-
|
|
Oct 15
2021
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Payment of exercise price or tax liability
|
Direct |
145
-1.98%
|
$5,075
$35.1 P/Share
|
|
Oct 15
2021
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
BUY
Exercise of conversion of derivative security
|
Direct |
417
+5.39%
|
-
|
|
Aug 31
2021
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
151
+0.35%
|
$4,983
$33.8 P/Share
|
|
Aug 31
2021
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
BUY
Other acquisition or disposition
|
Direct |
431
+8.52%
|
$14,223
$33.8 P/Share
|
|
Aug 31
2021
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Other acquisition or disposition
|
Direct |
166
+0.38%
|
$5,478
$33.8 P/Share
|
|
Aug 31
2021
|
Brett P Monia Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
355
+0.7%
|
$11,715
$33.8 P/Share
|